Aktienanalyse wird geladen …
ABBV · NYSE · Pharmaceuticals · USA
264,87 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 61,16 Mrd. | 4,23 Mrd. | 2,36 $ | 1,77 Mrd. | 3,6 Mio · 0,2 % | 3,6 Mio · 0,2 % | 70,2 % | 6,9 % | 10,05 $ | 0,54 $ | 6,65 $ |
| 2024 | 56,33 Mrd. | 4,28 Mrd. | 2,39 $ | 1,77 Mrd. | 3,4 Mio · 0,2 % | 3,4 Mio · 0,2 % | 70 % | 7,6 % | 10,06 $ | 0,51 $ | 6,29 $ |
| 2023 | 54,32 Mrd. | 4,86 Mrd. | 2,72 $ | 1,77 Mrd. | 2,8 Mio · 0,2 % | 7,8 Mio · 0,4 % | 62,4 % | 9 % | 12,44 $ | 0,42 $ | 5,99 $ |
| 2022 | 58,05 Mrd. | 11,84 Mrd. | 6,63 $ | 1,78 Mrd. | 2,5 Mio · 0,1 % | 1,5 Mio · 0,1 % | 70 % | 20,4 % | 13,64 $ | 0,38 $ | 5,71 $ |
| 2021 | 56,2 Mrd. | 11,54 Mrd. | 6,45 $ | 1,78 Mrd. | 2,6 Mio · 0,1 % | — | 69 % | 20,5 % | 12,37 $ | 0,39 $ | 5,31 $ |
| 2020 | 45,8 Mrd. | 4,62 Mrd. | 2,72 $ | 1,67 Mrd. | 2,8 Mio · 0,2 % | — | 66,4 % | 10,1 % | 10,04 $ | 0,45 $ | 4,84 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 16,99 Mrd. | 3,61 Mrd. | 2,04 $ | 1,77 Mrd. | — | 21,3 % | 1,76 $ |
| Q1 2026 | 15 Mrd. | 695 Mio. | 0,39 $ | 1,77 Mrd. | — | 4,6 % | 2,01 $ |
| Q4 2025 | 16,62 Mrd. | 1,82 Mrd. | 1,02 $ | 1,77 Mrd. | 72,6 % | 10,9 % | 2,76 $ |
| Q3 2025 | 15,78 Mrd. | 186 Mio. | 0,10 $ | 1,77 Mrd. | — | 1,2 % | 3,75 $ |
| Q2 2025 | 15,42 Mrd. | 938 Mio. | 0,53 $ | 1,77 Mrd. | — | 6,1 % | 2,76 $ |
| Q1 2025 | 13,34 Mrd. | 1,29 Mrd. | 0,73 $ | 1,77 Mrd. | — | 9,6 % | 0,79 $ |
| Q4 2024 | 15,1 Mrd. | -22 Mio. | -0,01 $ | — | 70,9 % | -0,2 % | 3,81 $ |
| Q3 2024 | 14,46 Mrd. | 1,56 Mrd. | 0,88 $ | 1,77 Mrd. | — | 10,8 % | 2,93 $ |
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs. The company’s portfolio includes branded prescription medicines and advanced therapies distributed through physicians, wholesalers, specialty pharmacies, healthcare facilities, and other healthcare channels. AbbVie also supports contract manufacturing services for selected biologics and pharmaceutical processes. Headquartered in North Chicago, Illinois, AbbVie operates as a research-driven healthcare business with a broad international footprint and a strong role in specialty medicine markets.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest ABBV und jede andere Aktie unbegrenzt.